Amp Volatility Score
Catalyst Info & Data Links
TITLE: SNDX-6352-503 in Chronic graft versus host disease (cGVHD) - Phase 1 Results
ClinicalTrial.gov (NCT03604692): A Phase 1/2 Study to Evaluate SNDX- 6352 in Subjects With Active cGVHD
WHAT IS THE NEXT CATALYST EVENT?
Phase 1 Results
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION / RATIONALE
Axatilimab (SNDX-6352) is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be a key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD (Learn more HERE).
Updated by HC
#SNDX, #Axatilimab, #SNDX-6352, #Chronic graft versus host disease, #cGVHD, #graft versus host disease, #bone marrow, #stem cell, #transplant, #white blood cell, #WBC,
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post